HER2 heats up as Seagen licenses RemeGen ADC for $2.6bnSeagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate Share XHER2 heats up as Seagen licenses RemeGen ADC for $2.6bnhttps://pharmaphorum.com/news/her2-heats-up-as-seagen-licenses-remegen-adc-for-2-6bn/
Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLRoche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed Share XArmed with phase 3 data, Roche preps filing for Polivy in first-line DLBCLhttps://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/
BMS pays $650m upfront for Eisai’s first ADC candidate for cancerJapan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing Share XBMS pays $650m upfront for Eisai’s first ADC candidate for cancerhttps://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/
Ambrx tries another IPO as it chases down HER2 rivalsCalifornia biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share XAmbrx tries another IPO as it chases down HER2 rivalshttps://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/
Enhertu cleared for NHS use via Cancer Drugs FundNICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the Share XEnhertu cleared for NHS use via Cancer Drugs Fundhttps://pharmaphorum.com/news/enhertu-cleared-for-nhs-use-via-cancer-drugs-fund/
Astellas, Seagen seek speedy reviews of Padcev in bladder cancerThe next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster Share XAstellas, Seagen seek speedy reviews of Padcev in bladder cancerhttps://pharmaphorum.com/news/astellas-seagen-seek-speedy-reviews-of-padcev-in-bladder-cancer/
Pyxis follows Pfizer alliance with $152m fundraising for cancer pipelineFresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in Share XPyxis follows Pfizer alliance with $152m fundraising for cancer pipelinehttps://pharmaphorum.com/news/pyxis-follows-pfizer-alliance-with-152m-fundraising-for-cancer-pipeline/
Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
FDA sets May date for verdict on ADC’s lymphoma drug LoncaADC Therapeutics could claim its first product approval in the US next May, after the FDA started a Share XFDA sets May date for verdict on ADC’s lymphoma drug Loncahttps://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/
